European Commission
Directorate C
Public Health and Risk Assessment
Health & Consumer Protection Directorate general

GRANT AGREEMENT
n° 2007121

EUROCHIP-III
European Cancer Health Indicator Project-III
Common Action

ANNEX 07 - LITHUANIA
MEDIA GUIDE on
CERVICAL CANCER IN LITHUANIA

Media Guide prepared in original language by ESO for Lithuania
in the framework of the EUROCHIP-3 Work Package 4 (English version)

Training materials copyright European School of Oncology, Peter McIntyre & Anna Wagstaff.
Please credit any use made of materials.
Not to be used for commercial gain

This publication arises from the project EUROCHIP-3 which has received funding from the European Union in the framework of the Health Programme
Cervical cancer is preventable and curable. So why do around 240 women in Lithuania die from this disease every year?

*This media guide won’t tell you the answer*

*But it could help you ask the right questions*
Too many deaths

Every year around 240 women die of a cancer that could have been prevented. Cervical is one of the most common cancers in women, and if it is left to grow undetected and untreated, it is fatal.

It is possible to prevent women developing cervical cancer, because ‘early warning signs’ can be detected in the cervical cells long before they become cancerous. And even after a cancer has developed, a cure is possible so long as it is caught at an early stage.

Many of the women who die of cervical cancer are in their forties and fifties, or even younger. Their death can deprive young children of a mother, families of a breadwinner, and parents of daughter’s care.

So why are these unnecessary deaths still happening? This media guide is designed to help journalists like you find out.

What causes cervical cancer?

Cervical cancer grows in the tissue of the narrow passage between the top of the vagina and the uterus or womb, sometimes known as the neck of the womb.

Almost all cervical cancers are caused by becoming infected with certain variants of the human papillomavirus (HPV). As with most viruses, in most cases HPV infection lasts for no more than a few weeks or months before it is cleared from the body – it produces no symptoms, and no is harm done. When infections do not clear, however, the HPV-infected cells may become ‘precancerous’. This is usually takes many years or even decades. While some precancerous cells can heal by themselves, there is a risk that they may turn into an invasive cancer if they are not detected and treated early.

The HPV virus is caught by having sex with someone who is already infected. While having many sexual partners does increase the risk, all it takes to catch the virus is one partner.

How is cervical cancer prevented?

Checking for warning signs

It takes a long time for the cellular changes resulting from HPV infection to lead to the beginnings of a cancer.

During this period, precancerous changes in the cells can be clearly seen under a microscope, so long as the sampling and analysis is done according to validated methods, and regular checks are made for quality control, as defined by the European Guidelines for Quality Assurance of Cervical Cancer Screening and Diagnosis and other international standards.
The conventional test for cervical cancer and precancerous abnormalities is called the Pap test (named after its developer, George Papanikolau); it is also known as the cervical smear test. Though other options are available, such as testing the DNA of cervical cells for the presence of HPV virus, these are not yet in widespread use.

All tests involve taking a cervical smear – scraping some cells off the cervix wall. This procedure can be done by almost any properly trained health worker in almost any setting. The cell samples are sent off to a laboratory for examination by experienced cytology assistants (cytotechnicians) and, when indicated, by cytopathologists.

If the cells show possible warning signs of cervical cancer, the woman is referred for tests to confirm the diagnosis, and is referred for treatment if the test shows positive. The tissue at risk is then removed before any cancer has had time to develop, and the woman should be referred for careful follow-up for up to five years.

The evidence shows that undergoing a Pap test once every three to five years will pick up 80% of potential cervical cancers before the cells have turned cancerous. So long as the treatment and follow-up is done according to the guidelines, it is possible to prevent precancerous cells developing into cancer in more than 99% of cases. Not all cancers can be diagnosed in the precancerous phase, but even if the cells have turned cancerous (or malignant), it is still possible to cure the disease so long as it is picked up early.

**Vaccines**

Vaccination against the HPV virus also helps to prevent cervical cancer. Two vaccines are now available that have been shown to be effective in preventing HPV 16 and HPV 18 infections, the two strains of HPV virus that are responsible for around 70% of cases of cervical cancer. However, they are not effective against all cancer-causing HPV strains, and they cannot prevent cervical cancer developing in women who have already contracted the HPV virus. For this reason, the European recommendation is that HPV vaccination can be used in addition to Pap tests but should not replace regular screening.

Both vaccines are administered in three doses given over six months. Like all vaccination programmes, the effect is greatest when coverage is high. Many European countries are now introducing HPV vaccination programmes successfully. In some countries, controversy about vaccinating children or young teenagers against a sexually transmitted disease has affected uptake. Many countries have decided not to introduce a programme of HPV vaccination, possibly on the grounds of affordability.

Gardasil is manufactured by the US pharmaceutical company Merck & co and is effective against HPV 6, 11, 16 and 18. Cervarix is manufactured by GlaxoSmithKline and is effective against HPV 16 and 18.
How can Lithuania reduce the death toll from cervical cancer?

There is a very strong consensus based on evidence from decades of experience in many European countries that the best way to cut the number of cases of cervical cancer, and the number of deaths, is through a national cervical cancer screening programme.

National cervical cancer screening programmes:

- Invite healthy women for regular screening visits using the Pap test,
- Are organised at a regional or national level and involve all women in a certain age range (usually at least 30 to 60), who are invited for screening at regular intervals (every three to five years is the recommended interval),
- Systematically recall women for further examination and, if necessary, treatment when cells appear abnormal or suspect,
- Have quality assurance built in to ensure that all aspects of the programme are working to a high standard – the attendance is high, the sampling of cervical cells is properly done, the lab analysis is accurate, the results are reported in a timely fashion, the woman is recalled for further investigations and referred for treatment, where appropriate, and treatment is carried out to a high level,
- Promote a high level of attendance through public awareness campaigns, effective communication, and ensuring screening is accessible. Women will be more likely to respond to invitations if they are addressed to them in person, if they contain clear and credible information (see box), and if the screening test is free or very cheap, and can be done in a convenient place at a convenient time.

These sorts of organised, systematic national programmes have been shown to be far more effective than relying on ‘opportunistic screening’, where Pap tests may be available, even free of charge, but rely on the patient or the doctor to take the initiative. Tests done opportunistically lack the quality control of the sampling, analysis, treatment and follow-up that is built into well-organised screening programmes. Opportunistic screening is also a very inefficient way to use health resources, as it results in large numbers of women never being screened for cervical cancer, while others may be screened far more frequently than is necessary.
Convincing women to attend cervical screening is one of the big challenges particularly in the early stages of a national screening programme.

Women will be more likely to attend screening if the invitation:

- Is addressed to them in person and makes clear that cervical screening is a health check-up for women like them
- Clearly explains what level of risk they face of developing cervical cancer and how effective screening is at protecting against that risk
- Tells them how the Pap test is performed: how long does it take, does it hurt, who will do it, what will be required of them
- Tells them what will happen to their sample, when they can expect their results, who will have access to their results
- Explains that they may be recalled for further tests, and what this could mean (usually this happens when tests are unreadable or inconclusive; even where abnormalities are found, they may not pose a danger of cancer)
- Tells them where to go for further information

**The evidence from Finland**

The experience of countries like Finland, which was the first country to establish a cervical cancer screening programme, shows how effective these national screening programmes can be. Finland pioneered cervical cancer screening in 1962. In 1976, 14 years later, it was able to show that women who had been regularly screened were five time less likely to develop cervical cancer than the rest of the population. Figures from 2008 (globocan.iarc.fr) show that women in Lithuania are almost seven times more likely to die of cervical cancer than women in Finland, and more than three times as likely to die as the EU average.

**Cervical cancer screening in Lithuania**

A national screening programme started in July 2004, targeting all women aged 30–60. In 2008 it was extended to include women in the 25–29 age bracket. Ten pathology laboratories across the country have been certified to carry out analysis of cervical smears. Primary health care centres are responsible for carrying out the Pap tests within the national screening programme. The tests are free of charge for women who are registered with a GP and have health insurance. GPs or a member of their team are responsible for giving information to women about cervical screening. However, they do not send out personal invitations, but tend instead to rely on informing women about the programme when they attend their primary health care centre for an unrelated health problem. It is then up to the woman to take the initiative to book herself in for a test. Some primary health care centres show a much higher rate of screening uptake than others.
In the first three years of testing, 44% of the women in the target age group attended cervical screening. This means a majority of women in Lithuania are still not taking steps to protect themselves from cervical cancer.

Two pilot studies have shown that sending a personal invitation to attend screening to women who have not made appointments on their own initiative can double the take-up rate of screening tests. The pilot projects, which were carried out in Pakruojis and Panevėžys municipalities, also showed a higher rate of potentially precancerous abnormal smears among women who had attended screening in response to a personal invitation than among those who had arranged to be tested on their own initiative. This indicates that sending personal invitations is particularly effective at women at higher risk of developing cervical cancer.

Including detailed information about the risks of cervical cancer and the benefits of screening, and backing this up with a public information campaign, also proved effective at pushing up the attendance rate.

**Unnecessary Deaths from Cervical Cancer – Covering the Story**

If Lithuania does not improve its record in preventing cervical cancer, women will continue to die unnecessarily. As a journalist, you have a vital role to play in telling the story of these unnecessary deaths, and in raising awareness about the risks of cervical cancer and how women can protect themselves. Journalists also have a responsibility to take a critical look at the way current policies and programmes for preventing cervical cancer are functioning, and to investigate how they might be improved.

Why do some women attend screening and others not? Would the additional cost of sending personal invitations to attend cervical cancer screening be justified by the lives saved and the suffering prevented? Are greater efforts needed to raise awareness of the existence of the screening programme and provide credible information about the risks of cervical cancer and the benefits of participating in the screening programme? Can the media play a role here?

If Lithuania could replicate what was achieved in Finland, the number of women dying from cervical cancer each year would drop, over time, from around 240 to around 35. Good media coverage that highlights the problem and explores solutions can make all the difference.
Contacts & Further information

Contacts
Dr. Rūta Kurtinaitienė, gynaecologist, Vilnius University Hospital Santariškių Klinikos. rkurtinaitiene@yahoo.com
Dr. Jolita Rimienė, pathologist, National centre of pathology. Jolita.Rimiene@vpc.lt
Aušrutė Armonavičienė, Ministry of Health. ausrute.armonaviciene@sam.lt

Family Planning and Sexual Health Association http://www.tavogyvenimas.lt/
Centre for Communicable Diseases and AIDS http://www.ulac.lt/
European cervical cancer association http://www.ecca.info/

Further Information
http://www.vlk.lt
http://www.lgs.lt/
http://www.lsvieikata.lt/
http://www.sam.lt/
http://www.lmb.lt/
http://www.bpg.lt
http://www.lrs.lt
http://www.medicina.lt
http://www.imed.lt
http://www.tv.lt/tvp/sveikatos-kodas

This media guide was produced by Anna Wagstaff and Peter McIntyre on behalf of the European School of Oncology (www.eso.net) as part of EUROCHIP-3 project funded by the European Commission Directorate for Health and Consumer Protection (DG SANCO) and conducted by the Fondazione IRCCS “Istituto Nazionale dei Tumori” in Milan in collaboration with the European School of Oncology.

Expert advice from: Ahti Anttila, research director at the Finnish Mass Screening Registry (Ahti.Anttila@cancer.fi), Ruta Kurtinaitiene, gynaecologist at Vilnius University (ruta.kurtinaitiene@takas.lt) and Jolita Rimienė, xxxxxxxxx (Jolita.Rimiene@vpc.lt)
Translation by: Lisa Nitti, www.lisanitti.com
Design by Harris DPI, www.harrisdpi.co.uk

<caption for image>

Good communication is important to the success of a screening programme.